Trial Profile

A Phase 1/2, Open-Label, Multi-Center, Dose Escalation, Dose Expansion, and Single Repeat Dose Study of TSRA-196 in Adults With the PiZZ Genotype Who Have Lung and/or Liver Disease Associated With Severe Alpha-1 Antitrypsin Deficiency

Status: Not yet recruiting

Phase of Trial: Phase I/II

Latest Information Update: 27 Jan 2026

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs TSRA 196 (Primary)
Indications Alpha 1-antitrypsin deficiency; Bronchiectasis; Emphysema; Hepatic fibrosis
Focus Adverse reactions; First in man; Therapeutic Use
Sponsors Tessera Therapeutics

12 Jan 2026 According to a Tessera Therapeutics, the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application for TSRA-196, for alpha-1 antitrypsin deficiency (AATD). The Company has also received Australian Human Research Ethics Committee (HREC) approval to begin the Phase 1/2 clinical trial.
17 Nov 2025 New trial record

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com